Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMP0N4U)

Drug Name
PD173074 Drug Info
Cross-matching ID
PubChem CID
1401
ChEBI ID
CHEMBL189584
CAS Number
CAS 219580-11-7
TTD Drug ID
D0VF6E

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.51 0.00e+0 19/20 (95%) MSMO1;SQLE;DHCR7;...
Terpenoid backbone biosynthesis 2.29 0.00e+0 18/22 (81.82%) HMGCS1;IDI1;ACAT2;...
Biosynthesis of unsaturated fatty acids 1.98 5.48e-3 21/27 (77.78%) SCD;ELOVL6;FADS1;...
Cysteine and methionine metabolism 1.90 8.21e-3 43/50 (86%) PSAT1;PHGDH;CBS;...
Butanoate metabolism 1.83 2.46e-2 23/28 (82.14%) HMGCS1;ACAT2;AACS;...
Synthesis and degradation of ketone bodies 1.82 2.05e-2 9/10 (90%) HMGCS1;ACAT2
Glycine, serine and threonine metabolism 1.78 2.82e-2 31/40 (77.5%) PSAT1;PHGDH;CBS;...
One carbon pool by folate 1.76 3.08e-2 15/20 (75%) MTHFD2;SHMT2;ATIC;...
Tyrosine metabolism 1.73 4.11e-2 30/36 (83.33%) ADH5;ALDH3A1;GOT1;...
Homologous recombination 1.69 4.93e-2 35/41 (85.37%) BRCA1;BARD1;RAD51C;...
TNF signaling pathway -1.57 4.93e-2 103/112 (91.96%) VEGFC;CHUK;MAP2K3;...
Pertussis -1.58 4.69e-2 64/76 (84.21%) ITGB1;CXCL5;IL6;...
Osteoclast differentiation -1.59 4.43e-2 117/127 (92.13%) LILRB1;SIRPA;CYLD;...
Galactose metabolism -1.59 4.55e-2 26/31 (83.87%) GLB1;LALBA;GAA;...
ABC transporters -1.61 4.00e-2 37/45 (82.22%) ABCA6;ABCA4;ABCD3;...
Tuberculosis -1.62 3.96e-2 159/180 (88.33%) TNF;RAB5C;ARHGEF12;...
Natural killer cell mediated cytotoxicity -1.62 4.03e-2 99/131 (75.57%) KRAS;MAP2K1;SOS1;...
Viral protein interaction with cytokine and cytokine re... -1.65 3.27e-2 84/100 (84%) IL20RA;CCL13;CXCL3;...
Toll-like receptor signaling pathway -1.65 3.26e-2 94/104 (90.38%) TLR7;TLR8;MAP3K8;...
Neutrophil extracellular trap formation -1.66 3.24e-2 101/189 (53.44%) TLR7;TLR8;GSDMD;...
Hematopoietic cell lineage -1.67 2.81e-2 90/99 (90.91%) ITGB3;TNF;ITGA2B;...
Carbohydrate digestion and absorption -1.68 2.64e-2 37/47 (78.72%) ATP1B2;AKT1;MGAM;...
Systemic lupus erythematosus -1.69 2.39e-2 45/135 (33.33%) C9;CD40;TNF;...
Viral myocarditis -1.72 1.97e-2 53/60 (88.33%) HLA-E;CASP9;EIF4G3;...
African trypanosomiasis -1.73 1.64e-2 32/37 (86.49%) TNF;PRKCB;IL1B;...
Th1 and Th2 cell differentiation -1.75 1.43e-2 80/92 (86.96%) IFNGR2;NOTCH1;RUNX3;...
Chagas disease -1.86 5.97e-3 93/102 (91.18%) CHUK;CCL2;TNF;...
Allograft rejection -1.89 3.67e-3 32/38 (84.21%) CD40;HLA-E;TNF;...
Antigen processing and presentation -1.90 2.98e-3 60/78 (76.92%) NFYA;RFX5;HSPA5;...
Autoimmune thyroid disease -1.93 1.09e-3 46/53 (86.79%) HLA-DPA1;HLA-DPB1;FASLG;...
Graft-versus-host disease -1.95 0.00e+0 32/42 (76.19%) HLA-E;TNF;IL1B;...
Asthma -1.98 0.00e+0 25/31 (80.65%) EPX;HLA-DMB;CCL11;...
Legionellosis -2.01 0.00e+0 51/57 (89.47%) SAR1A;CXCL3;TNF;...
Staphylococcus aureus infection -2.02 0.00e+0 72/95 (75.79%) FPR1;DEFA4;C5AR1;...
Inflammatory bowel disease -2.03 0.00e+0 58/65 (89.23%) TNF;IL1B;IFNGR2;...
Rheumatoid arthritis -2.03 0.00e+0 78/93 (83.87%) CXCL3;CCL2;TNF;...
Amoebiasis -2.05 0.00e+0 99/102 (97.06%) TGFB2;PRKACB;MUC2;...
IL-17 signaling pathway -2.06 0.00e+0 84/94 (89.36%) CHUK;CXCL3;CCL2;...
Type I diabetes mellitus -2.09 0.00e+0 38/43 (88.37%) HLA-E;TNF;IL1B;...
Leishmaniasis -2.25 0.00e+0 67/77 (87.01%) TNF;ITGA4;PRKCB;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 3H, 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
LNCaP CVCL_0395 Homo sapiens 0.04uM - 10uM 3H, 24H
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H